These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32483771)

  • 1. Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
    Puram RV; Erdil RM; Weber BN; Knelson EH; Van Beuningen AM; Wallwork R; Gilyard SN; Curtis BR; Ranganathan R; Leaf RK; Malhotra R
    Thromb Haemost; 2020 Jul; 120(7):1137-1141. PubMed ID: 32483771
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction.
    Attaya S; Kanthi Y; Aster R; McCrae K
    Platelets; 2009 Feb; 20(1):64-7. PubMed ID: 19172524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario.
    Bhatia N; Sawyer RD; Ikram S
    Methodist Debakey Cardiovasc J; 2017; 13(4):248-252. PubMed ID: 29744018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis.
    Karathanos A; Lin Y; Dannenberg L; Parco C; Schulze V; Brockmeyer M; Jung C; Heinen Y; Perings S; Zeymer U; Kelm M; Polzin A; Wolff G
    Can J Cardiol; 2019 Nov; 35(11):1576-1588. PubMed ID: 31542257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
    Yang EH; Perez E; Zhiroff KA; Burstein S
    Tex Heart Inst J; 2011; 38(2):174-8. PubMed ID: 21494531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
    Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
    J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Kleiman NS
    Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura.
    Ozsoylu S
    Am J Hematol; 1996 Apr; 51(4):328. PubMed ID: 8602636
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB
    Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.
    Lapostolle F; Van't Hof AW; Hamm CW; Stibbe O; Ecollan P; Collet JP; Silvain J; Lassen JF; Heutz WMJM; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Ten Berg J; Zeymer U; Licour M; Tsatsaris A; Montalescot G;
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):173-183. PubMed ID: 30353444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
    Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
    J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eptifibatide-induced thrombocytopenia and thrombosis.
    Epelman S; Nair D; Downey R; Militello M; Askari AT
    J Thromb Thrombolysis; 2006 Oct; 22(2):151-4. PubMed ID: 17008982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
    Abrams CS; Cines DB
    Thromb Haemost; 2002 Dec; 88(6):888-9. PubMed ID: 12529733
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.
    Tavenier AH; Hermanides RS; Fabris E; Lapostolle F; Silvain J; Ten Berg JM; Lassen JF; Bolognese L; Cantor WJ; Cequier Á; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Ecollan P; Collet JP; Willems FF; Diallo A; Vicaut E; Hamm CW; Montalescot G; van 't Hof AWJ;
    Thromb Haemost; 2020 Jan; 120(1):65-74. PubMed ID: 31752042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.
    Greinacher A; Fuerll B; Zinke H; Müllejans B; Krüger W; Michetti N; Motz W; Schwertz H
    Blood; 2009 Aug; 114(6):1250-3. PubMed ID: 19429867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the Role for Glycoprotein IIb/IIIa Inhibitor Use in the Catheterization Laboratory in the Current Era?
    Rubboli A; Patti G
    Curr Vasc Pharmacol; 2018; 16(5):451-458. PubMed ID: 29345590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.